Abstract 1044P
Background
For product development, GMP production, quality control for product release and immune monitoring of patient samples, three methods are typically used to identify rTCR expression in TCR-T populations: (1) detection of an extra tag that is co-expressed with the rTCR; (2) binding of antibodies specific for TCR Vß-chains, or (3) rTCR binding of peptide-HLA multimers. The latter two approaches must be tailored for each rTCR and high-quality reagents may not be readily available.
Methods
Using bioinformatics and 3D modeling of TCRs, novel synthetic epitopes were designed and inserted at different positions in multiple rTCR sequences. Internally tagged rTCRs were assessed for surface expression, functionality and target specificity, as well as for binding of an antibody (TraCR) detecting the synthetic epitopes of different length.
Results
Identifying a unique, synthetic epitope (UniTope) and optimal insertion sites localized in the rTCR constant regions permitted highly specific detection by the TraCR antibody. The UniTope & TraCR combination unambiguously distinguishes rTCRs expressed in recipient T cells from all endogenous TCRs found in PBL. The integrated UniTope tag exclusively binds TraCR antibody, and not alter functionality, established safety profiles or expression levels of any of the assessed rTCRs.
Conclusions
UniTope & TraCR is a universal detection system for rTCRs easy to adapt for multi-parameter flow cytometry. Seamless integration of UniTope in any rTCR structure bypasses need for co-expression of a separate gene sequence to universally tag rTCR-expressing T cells. Providing a standardized detection system, UniTope & TraCR simplifies supply and validation of quality control assays for TCR-T therapies covering all rTCRs, providing precise information for drug product dosing. It allows easy visualization, isolation and enrichment of TCR-T cells for direct study. GMP-grade TraCR can be applied for drug product enrichment and potentially also to trace TCR-T cell localization and persistence in vivo, supporting immune monitoring in patients. The UniTope & TraCR system is a high precision technology that facilitates optimized development of TCR-T therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
917P - Automatic characterization of spatial arrangement of tumor-infiltrating lymphocytes identifies oral cavity squamous cell carcinoma patients with poorer prognosis
Presenter: German Corredor
Session: Poster session 03
918P - Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancer
Presenter: Gema Bruixola
Session: Poster session 03
919P - Predictive multi-omic signature in locally advanced laryngeal/hypopharyngeal (LH) squamous cell carcinoma (SCC) treated with induction chemotherapy (IC)
Presenter: Paolo Bossi
Session: Poster session 03
920P - Genomic landscape of head and neck cancer in Asia: A comprehensive meta-analysis of 1016 samples
Presenter: Sewanti Limaye
Session: Poster session 03
Resources:
Abstract
921P - Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer
Presenter: Michael Saerens
Session: Poster session 03
922P - Genomic instability as a biomarker for advanced cancer of the head and neck
Presenter: Filippo Dall'Olio
Session: Poster session 03
923P - Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHN
Presenter: Natasha Honoré
Session: Poster session 03
924P - Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection
Presenter: Darren Wan-Teck Lim
Session: Poster session 03
925P - External validation of the CD8 radiomics signature as a prognostic marker in recurrent or metastatic head and neck cancer treated with nivolumab
Presenter: Laville Adrien
Session: Poster session 03
926P - Genetic alteration in olfactory neuroblastoma: Unraveling carcinogenesis mechanisms and chemotherapy resistance through whole exome sequencing analysis
Presenter: Haruhi Furukawa
Session: Poster session 03